Literature DB >> 22045517

Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement.

Muir Morton1, Sarah Edmonds, Aislinn M Doherty, Ajay Dhaygude, Matthew Helbert, Mike Venning.   

Abstract

This study is an audit and a comparison of major infective complications in patients with granulomatosis with polyangiitis (GPA) and systemic lupus erythematosis (SLE). Data were collected on consecutive patients attending a single treatment approach, multidisciplinary vasculitis centre who met diagnostic criteria for GPA and SLE from 01/01/2006 to 30/06/2006. Immunosuppressive treatment is used in this clinic with guidelines targeting avoidance of neutropenia. For each patient, documentation was made of disease presentation, organ involvement and therapy used. A history of major infections requiring hospital admission and intravenous antimicrobials pre- and post-diagnosis was recorded. Patients with GPA received a higher cumulative dose of cyclophosphamide, had a higher median age, shorter period of follow-up and had lower mean and nadir absolute lymphocyte counts and nadir neutrophil counts. GPA patients had more major infections per patient years (P = 0.0027) and respiratory tract infections (P = 0.0031) per patient years. Relative risk (RR) of major infection was significantly increased with methylprednisolone, RR 11.1 (P = <0.0001), cyclophosphamide, RR 2.0 (P = 0.0246) and the intensive phase of treatment, RR 13.3 (P = <0.0001). Marked lymphopenia was common in both groups during follow-up and was associated with an increased risk of major infection (P = 0.0020). Major infections, in particular respiratory tract infections, are more common in those treated for GPA than SLE. This may be due to a combination of factors including greater doses and duration of methyprednisolone and cyclophosphamide. We recommend treatment strategies that aim not only to avoid neutropenia but that also identify lymphopenia as a risk factor for major infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045517     DOI: 10.1007/s00296-011-2151-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  39 in total

1.  The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient.

Authors:  Mumtaz Patel; Alexandra M Clarke; Ian N Bruce; Deborah P M Symmons
Journal:  Arthritis Rheum       Date:  2006-09

2.  BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

Authors:  C Lapraik; R Watts; P Bacon; D Carruthers; K Chakravarty; D D'Cruz; L Guillevin; L Harper; D Jayne; R Luqmani; J Mooney; D Scott
Journal:  Rheumatology (Oxford)       Date:  2007-09-05       Impact factor: 7.580

3.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

Review 4.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Authors:  Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

5.  [Infectious complications in systemic lupus erythematosus: a series of 146 patients].

Authors:  M Jallouli; M Frigui; S Marzouk; I Mâaloul; N Kaddour; Z Bahloul
Journal:  Rev Med Interne       Date:  2008-04-25       Impact factor: 0.728

6.  Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus.

Authors:  J C Nossent; A J Swaak
Journal:  Q J Med       Date:  1991-07

7.  Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients.

Authors:  C Charlier; C Henegar; O Launay; C Pagnoux; A Berezné; B Bienvenu; P Cohen; L Mouthon; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-05-26       Impact factor: 19.103

8.  Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

Authors:  A Sinclair; G Appel; M A Dooley; E Ginzler; D Isenberg; D Jayne; D Wofsy; N Solomons
Journal:  Lupus       Date:  2007       Impact factor: 2.911

9.  Immune response to pneumococcal conjugate vaccination in asplenic individuals.

Authors:  Elaine Stanford; Fiona Print; Michelle Falconer; Kenneth Lamden; Samuel Ghebrehewet; Nick Phin; David Baxter; Matthew Helbert; Rosemary McCann; Nick Andrews; Paul Balmer; Ray Borrow; Edward Kaczmarski
Journal:  Hum Vaccin       Date:  2009-02-07

10.  Predictors of major infections in systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Nerea Olivares; Ioana Ruiz-Arruza; Agustin Martinez-Berriotxoa; Maria-Victoria Egurbide; Ciriaco Aguirre
Journal:  Arthritis Res Ther       Date:  2009-07-15       Impact factor: 5.156

View more
  4 in total

1.  Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.

Authors:  Rémi Goupil; Soumeya Brachemi; Annie-Claire Nadeau-Fredette; Clément Déziel; Yves Troyanov; Valery Lavergne; Stéphan Troyanov
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

Review 2.  [Screening investigations during intensified immunosuppression in children and adolescents. Part 1].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

3.  Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Michiko Morishita; Ken-Ei Sada; Yoshinori Matsumoto; Keigo Hayashi; Yosuke Asano; Sumie Hiramatsu Asano; Keiji Ohashi; Yoshia Miyawaki; Eri Katsuyama; Haruki Watanabe; Tomoko Kawabata; Jun Wada
Journal:  PLoS One       Date:  2019-07-10       Impact factor: 3.240

4.  The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort.

Authors:  Yi-Yun Shi; Zhi-Ying Li; Ming-Hui Zhao; Min Chen
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.